Business
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expected in the second half of 2024 Enrollment progressing in the
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expected in the second half of 2024 \nEnrollment progressing in the Phase 2b CORAL dose-ranging trial of Haduvio for the treatment of chronic cough in IPF patients \nHuman Abuse Potential Study more than 50% enrolled\nManagement to host a conference call and webcast today at 4:30 p.m. ET \nNEW HAVEN, Conn., March 20, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced financial results for the quarter and year ended December 31, 2023, as well as provided business updates.\n\n \n \n \n \n \n \n\n \nTrevi is expecting 2024 to be a milestone year with important data readouts in chronic cough in the second half\"I am proud of the progress Trevi has made in 2023, with the initiation of clinical trials in the fourth quarter for RCC, chronic cough in IPF, and the final part of the Human Abuse Potential (HAP) study,\" said Jennifer Good, President and CEO of Trevi Therapeutics. \"All three of these trials are enrolling patients and we reaffirm our guidance to read out topline data in the second half of this year for the RCC trial and the HAP study. During this time, we also plan to complete and release the results of the sample size re-estimation (SSRE) for the chronic cough in IPF trial. We are expecting 2024 to be a milestone year of important data readouts in areas of chronic cough where there is a significant unmet need with no approved treatments in the United States.\"\nKey Business Updates\nPhase 2a RIVER trial for the treatment of RCC, in which we expect to enroll approximately 60 patients, was initiated in the fourth quarter of 2023. Enrollment continues across multiple sites with the majority of sites being activated in the first quarter of 2024. Topline data is expected in the second half of 2024. The RIVER trial will measure overall results, as well as results from the 1:1 stratification between patients with 10-19 coughs/hour (moderate 24-hour cough frequency) and those with ≥ 20 coughs/hour (high 24-hour cough frequency). Phase 2b CORAL trial for the treatment of chronic cough in IPF, in ...